Phentermine for Weight Loss: A Clinical Guide for Providers

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·12 min read

Phentermine is, by volume, the medication most clinicians actually reach for in medical weight loss. Long before semaglutide and tirzepatide reshaped the field, phentermine was — and remains — the most commonly prescribed appetite suppressant in the country. For providers building a weight-management practice, it is often the first pharmacologic tool they use: inexpensive, familiar, fast-acting, and supported by decades of clinical experience. The challenge is not whether it works, but using it well in the right patient, screening the contraindications that matter, and respecting its status as a controlled stimulant.

This guide situates phentermine within the broader field of medical weight loss and is written for clinicians who want an accurate, practical overview. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation, protocol, or substitute for current FDA labeling.

What is phentermine?

Phentermine is a sympathomimetic amine — a stimulant chemically related to amphetamine — that functions as a central appetite suppressant. As Dr. Greenleaf frames it in Empire's medical weight loss course, phentermine is simply “the most commonly prescribed appetite suppressant.” It has been in clinical use far longer than any of the newer metabolic agents, which is precisely why it remains a staple: providers know how it behaves, and the cost barrier is low.

Functionally, phentermine is best described as an amphetamine-like stimulant that decreases appetite. That single sentence captures both its usefulness and its caveats. The same adrenergic activity that quiets hunger also raises heart rate and blood pressure, which is why patient selection and monitoring — not the prescription itself — are where the clinical work lives.

How phentermine works

Phentermine works for weight loss by suppressing appetite, increasing energy expenditure, and acting on the parts of the brain that regulate appetite. Mechanistically, it increases neurotransmitter levels in the brain — chiefly norepinephrine, with smaller contributions from serotonin and dopamine. The rise in norepinephrine activates satiety signaling and decreases the sensation of hunger, so patients eat less without the constant pull of appetite.

The norepinephrine surge is also the source of phentermine's secondary effects. Catecholamine release modestly increases energy expenditure and produces the stimulant “sense of well-being” or energy that some patients notice. It is the same adrenergic mechanism, however, that drives the cardiovascular and sleep-related side effects discussed below — the receptor activity that suppresses appetite is inseparable from the activity that raises heart rate. Understanding that linkage is the key to using the drug safely: you are prescribing a stimulant, and the patient's cardiovascular baseline determines whether that is appropriate.

FDA status and controlled-substance scheduling

Phentermine is FDA-approved, and that approval is specifically for short-term use. It is indicated as an adjunct to a doctor-approved exercise plan, behavioral change, and a reduced-calorie diet — never as a standalone fix. The conventional interpretation of “short-term” is a course of no longer than about twelve weeks, though some studies have evaluated use up to six months. Any longer course is an off-label clinical decision that should follow current labeling and individualized judgment.

Phentermine is also a Schedule IV controlled substance. In the DEA framework, that classification signals a recognized but relatively low potential for abuse and dependence, alongside an accepted medical use. The practical implication for prescribers is real: phentermine requires the same prescribing discipline as other controlled stimulants — documentation, appropriate quantities, attention to refill patterns, and screening for a history of substance use. The short-term approval and the controlled-substance status are two sides of the same fact: this is an effective stimulant whose benefit is meant to be captured early in a structured program, not extended indefinitely.

Efficacy and the evidence

The efficacy data on phentermine are modest but real. In Dr. Greenleaf's summary of the literature, the average weight loss is about three percent of initial body weight after three months and five to seven percent after six months. That places phentermine well below the magnitude seen with modern GLP-1 and dual-agonist agents, but it is meaningful weight loss for an inexpensive, widely available oral medication — and for many patients a five-to-seven-percent reduction crosses the threshold of clinical benefit for blood pressure, glycemic control, and lipids.

An important, evidence-honest caveat is durability. Like the other older adrenergic appetite suppressants, phentermine's effect is concentrated in the short term, and weight can return once the medication stops. This is consistent with the broader principle that obesity behaves as a chronic, relapsing disease rather than a problem solved by a single brief course — a theme that runs through every medication in this class.

Phentermine is also frequently noted to work better in combination than alone, most notably when paired with topiramate. That combination is discussed in its own section below.

Side effects and safety

Because phentermine is a stimulant, its side-effect profile is predictable from its mechanism. The most clinically important effects are cardiovascular and stimulant-related: increased heart rate and blood pressure, insomnia, dry mouth, nervousness, and jitteriness. Many patients also report a stimulant sense of well-being and, less commonly, headache.

Dr. Greenleaf lists the common side effects as nervousness, dry mouth, a sense of well-being, and headache, with less common effects including heartburn, an unpleasant taste, skin itching, decreased sex drive, and insomnia. The cardiovascular signal is the one that drives monitoring: because the drug reliably raises heart rate and blood pressure, every patient needs a documented cardiovascular baseline and follow-up.

As a controlled stimulant, phentermine also carries a dependency potential — the basis for its Schedule IV status. This is not the high-risk dependence of stronger amphetamines, but it is real enough to warrant screening for a history of substance use and to favor the short, structured courses for which the drug is approved. There are also meaningful interaction cautions: phentermine should generally not be combined with pseudoephedrine, other stimulants such as methylphenidate, caffeine, tricyclic antidepressants, or alcohol, all of which can compound its adrenergic load.

Contraindications and cautions

Screening contraindications is the single most important safety step before prescribing phentermine, and the list follows directly from its stimulant pharmacology. Phentermine is contraindicated in:

• Cardiovascular disease — symptomatic or established cardiovascular disease, given the drug's effect on heart rate and blood pressure.
• Untreated hyperthyroidism — an already hyperadrenergic state that a stimulant can worsen.
• MAOI use — concurrent use, or use within the prior two weeks, of a monoamine oxidase inhibitor, because of the risk of a hypertensive crisis.
• Glaucoma — sympathomimetics can raise intraocular pressure.
• A history of substance use — given the controlled-substance status and dependency potential.
• Pregnancy or breastfeeding — pregnancy is not a time to be losing weight, even in patients with obesity, and weight-loss agents as a class are avoided.

Dr. Greenleaf also flags additional cautions worth screening: severe depression, untreated hyperthyroid disease, renal or liver disease, and age extremes — the drug is generally avoided in patients over sixty or under sixteen. Taken together, these contraindications make the point that phentermine is a good drug for the right patient — typically a metabolically healthy adult with obesity and a controlled cardiovascular profile — and the wrong drug for anyone whose physiology a stimulant could destabilize.

Combinations: phentermine-topiramate and beyond

Phentermine is often more effective in combination, and the best-established pairing is with topiramate. Topiramate independently supports weight loss — it has been associated with reductions in BMI, body weight, systolic blood pressure, and hemoglobin A1c — through a mechanism that is not fully understood but is believed to involve appetite suppression. Combining a morning sympathomimetic (phentermine) with topiramate produces additive weight loss, with clinical-trial results reaching roughly a ten percent reduction in body weight.

This combination is formalized in the FDA-approved product phentermine-topiramate (Qsymia), which — unlike phentermine alone — is approved for chronic weight management. The combination carries its own considerations, including cognitive and mood effects, cardiovascular morbidity signals, and a potential for birth defects that makes pregnancy testing before initiation a standard precaution. For a full treatment of the combination drug, see our companion guide on phentermine-topiramate (Qsymia).

Phentermine has also been studied in other off-label serotonergic combinations, and providers should understand where those strategies are evidence-supported versus experimental. The broader landscape of options is mapped in our overview of weight-loss medications.

Patient selection and monitoring

Patient selection for phentermine follows the standard obesity-pharmacotherapy threshold: a BMI at or above 30, or at or above 27 with weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidemia. Within that group, the ideal phentermine candidate is an adult whose cardiovascular system can tolerate a stimulant — normotensive or well-controlled, without symptomatic heart disease, and without the contraindications listed above.

Monitoring is built around the cardiovascular signal. Because phentermine reliably raises heart rate and blood pressure, a documented baseline and structured follow-up of both are non-negotiable; a patient whose blood pressure or heart rate climbs unacceptably on therapy needs the dose reconsidered or the drug stopped. Follow-up also tracks tolerability — sleep, jitteriness, dry mouth — and efficacy against the short-term benchmark, with the understanding that this is a time-limited tool within a larger lifestyle program. Deliberately, this overview does not specify milligram doses or titration schedules; those belong to current FDA labeling and individualized clinical judgment, and the specific starting points, dose adjustments, and combination schedules are covered in depth in Empire's training.

Phentermine's place in a weight-loss program

Phentermine is rarely the whole answer, and it was never meant to be. The FDA approval explicitly frames it as an adjunct to a reduced-calorie diet, exercise, and behavioral change — the medication suppresses appetite, but the diet and activity program is what produces durable change. For many practices, phentermine is the accessible, low-cost entry point to pharmacotherapy: a way to give a motivated patient an early win while lifestyle habits take hold, often before considering a longer-term agent.

It also sits within a much wider toolkit. As the obesity field has expanded, phentermine increasingly serves as one option among several — older adrenergic agents, the combination drugs, and the newer incretin-based therapies such as the GLP-1 receptor agonists. Providers comparing it with those agents will find context in our overviews of semaglutide and peptides for weight loss. The clinical art is matching the tool to the patient — and phentermine, used short-term in the right person, still earns its place.

How providers train to prescribe phentermine

Because phentermine is a controlled stimulant with a defined cardiovascular and contraindication profile, prescribing it well is a learned competency rather than an afterthought. The skill set is concrete: screen the contraindications that matter, establish and follow blood-pressure and heart-rate baselines, recognize when the short-term course should end, and know how and when to reach for combination strategies such as phentermine-topiramate. Empire's curriculum is built around exactly this kind of practical judgment, connecting phentermine to the full spectrum of medical weight loss options and to dedicated medical weight loss training for providers who want to build or expand a weight-management practice responsibly.